Status | In progress |
Process | STA 2018 |
ID number | 3836 |
Provisional Schedule
Committee meeting: 1 | 11 November 2021 |
Expected publication | 02 February 2022 |
Project Team
Project lead | Louise Jafferally |
Email enquiries
- If you have any queries please email TATeam4@nice.org.uk
Consultees
Companies sponsors | Janssen-Cilag (amivantamab) |
Others | Department of Health and Social care |
NHS England | |
NHS Herefordshire and Worcestershire CCG | |
NHS Hillingdon CCG | |
Welsh Government | |
Patient carer groups | Black Health Agency for Equality |
British Lung Foundation | |
Cancer Black Care | |
Cancer Equality | |
EGFR Positive UK | |
Helen Rollason Cancer Charity | |
Independent Cancer Patients Voice | |
Macmillan Cancer Support | |
Maggie’s Centres | |
Marie Curie | |
Roy Castle Lung Cancer Foundation | |
South Asian Health Foundation | |
Specialised Healthcare Alliance | |
Tenovus Cancer Care | |
UK Lung Cancer Coalition | |
Professional groups | Association of Cancer Physicians |
Association of Respiratory Nurse Specialists | |
British Geriatrics Society | |
British Institute of Radiology | |
British Psychosocial Oncology Society | |
British Society of Interventional Radiology | |
British Thoracic Oncology Group | |
British Thoracic Society | |
Cancer Research UK | |
Lung Cancer Nursing UK | |
National Heart and Lung Institute | |
Primary Care Respiratory Society UK | |
Royal College of General Practitioners | |
Royal College of Nursing | |
Royal College of Pathologists | |
Royal College of Physicians | |
Royal College of Radiologists | |
Royal Pharmaceutical Society | |
Royal Society of Medicine | |
Society and College of Radiographers | |
UK Clinical Pharmacy Association | |
UK Oncology Nursing Society |
Commentators
Associated guideline groups | National Guideline Alliance |
Associated public health groups | Public Health England |
Public Health Wales | |
Comparator companies | Accord Healthcare (docetaxel, carboplatin) |
Boehringer Ingelheim (nintedanib) | |
Bristol-Myers Squibb (nivolumab) | |
Consilient Health (carboplatin) | |
Eli Lilly and Company (pemetrexed) | |
Hospira UK (docetaxel, carboplatin) | |
MSD (pembrolizumab) | |
Roche products (atezolizumab) | |
Seacross Pharmaceuticals (docetaxel, pemetrexed) | |
General commentators | All Wales Therapeutic and Toxicology Centre |
Allied Health Professionals Federation | |
Board of Community Health Councils in Wales | |
British National Formulary | |
Care Quality Commission | |
Department of Health, Social Services and Public Safety for Northern Ireland | |
Healthcare Improvement Scotland | |
Medicines and Healthcare products Regulatory Agency | |
National Association of Primary Care | |
National Pharmacy Association | |
NHS Alliance | |
NHS Confederation | |
Scottish Medicines Consortium | |
Welsh Health Specialised Services Committee | |
Relevant research groups | Cochrane Lung Cancer Group |
Genomics England | |
Institute of Cancer Research | |
MRC Clinical Trials Unit | |
National Cancer Research Institute | |
National Cancer Research Network | |
National Institute for Health Research |
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
16 March 2021 | Invitation to participate |
13 January 2021 - 10 February 2021 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
01 September 2020 | In progress. DHSC referral received |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance